Lista de obras - Alexandre Vivot - Dominio Público Uruguay

A phase II, open-label, non-comparative study of Botulinum toxin in Restless Legs Syndrome

artículo científico publicado en 2012

Accuracy of repeated measurements of late-night salivary cortisol to screen for early-stage recurrence of Cushing's disease following pituitary surgery.

artículo científico publicado en 2014

Appraisal of cancer drugs: a comparison of the French health technology assessment with value frameworks of two oncology societies

scientific article published on 26 June 2019

Association of Alzheimer's related genotypes with cognitive decline in multiple domains: results from the Three-City Dijon study

artículo científico publicado en 2015

Bayesian analysis from phase III trials were underused and poorly reported: a systematic review

scientific article published on 04 April 2020

CD20 antigen may be expressed by reactive or lymphomatous cells of transformed mycosis fungoides: diagnostic and prognostic impact.

artículo científico publicado en 2013

Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000-2015.

artículo científico publicado en 2017

Evidence for Treatment-by-Biomarker interaction for FDA-approved Oncology Drugs with Required Pharmacogenomic Biomarker Testing

artículo científico publicado en 2017

Factors associated with post-marketing research for approved indications for novel medicines approved by both the FDA and EMA between 2005 and 2010: A multivariable analysis

artículo científico publicado en 2018

Guidance for pharmacogenomic biomarker testing in labels of FDA-approved drugs

artículo científico publicado en 2014

Impact of Biomarker-based Design Strategies on the Risk of False-Positive Findings in Targeted Therapy Evaluation

scientific article published on 30 August 2018

Impact of gag genetic determinants on virological outcome to boosted lopinavir-containing regimen in HIV-2-infected patients

artículo científico publicado en 2013

Improving on Tail-of-the-Curve Evaluation With the American Society of Clinical Oncology Value Framework

scientific article published on 01 October 2018

Jump, Hop, or Skip: Modeling Practice Effects in Studies of Determinants of Cognitive Change in Older Adults

artículo científico publicado en 2016

Living network meta-analysis was feasible when considering the pace of evidence generation

artículo científico publicado en 2018

Magnetisation transfer parameters and stroke outcome.

artículo científico publicado en 2015

Mapping of Crowdsourcing in Health: Systematic Review.

artículo científico publicado en 2018

Pharmacogenomic biomarkers as inclusion criteria in clinical trials of oncology-targeted drugs: a mapping of ClinicalTrials.gov.

artículo científico publicado en 2015

Post-marketing research and its outcome for novel anticancer agents approved by both the FDA and EMA between 2005 and 2010: A cross-sectional study.

artículo científico publicado en 2017

Postmarketing studies for novel drugs approved by both the FDA and EMA between 2005 and 2010: a cross-sectional study

artículo científico publicado en 2017

Rituximab for induction and maintenance therapy of granulomatosis with polyangiitis: a single-centre cohort study on 114 patients

article by Xavier Puéchal et al published 2 May 2018 in Rheumatology

Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France, 2004-2012

artículo científico publicado en 2013

Should we consider day-2 and day-3 embryo morphology before day-5 transfer when blastocysts reach a similar good quality?

artículo científico publicado en 2017

Use of Late-Life Expectancy for Assessing the Long-Term Benefit of Immune Checkpoint Inhibitors

scientific article published on 01 May 2019

Using an Alzheimer Disease Polygenic Risk Score to Predict Memory Decline in Black and White Americans Over 14 Years of Follow-up

artículo científico publicado en 2016

Lista de obras de Alexandre Vivot

A phase II, open-label, non-comparative study of Botulinum toxin in Restless Legs Syndrome

Accuracy of repeated measurements of late-night salivary cortisol to screen for early-stage recurrence of Cushing's disease following pituitary surgery.

Appraisal of cancer drugs: a comparison of the French health technology assessment with value frameworks of two oncology societies

Association of Alzheimer's related genotypes with cognitive decline in multiple domains: results from the Three-City Dijon study

Bayesian analysis from phase III trials were underused and poorly reported: a systematic review

CD20 antigen may be expressed by reactive or lymphomatous cells of transformed mycosis fungoides: diagnostic and prognostic impact.

Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000-2015.

Evidence for Treatment-by-Biomarker interaction for FDA-approved Oncology Drugs with Required Pharmacogenomic Biomarker Testing

Factors associated with post-marketing research for approved indications for novel medicines approved by both the FDA and EMA between 2005 and 2010: A multivariable analysis

Guidance for pharmacogenomic biomarker testing in labels of FDA-approved drugs

Impact of Biomarker-based Design Strategies on the Risk of False-Positive Findings in Targeted Therapy Evaluation

Impact of gag genetic determinants on virological outcome to boosted lopinavir-containing regimen in HIV-2-infected patients

Improving on Tail-of-the-Curve Evaluation With the American Society of Clinical Oncology Value Framework

Jump, Hop, or Skip: Modeling Practice Effects in Studies of Determinants of Cognitive Change in Older Adults

Living network meta-analysis was feasible when considering the pace of evidence generation

Magnetisation transfer parameters and stroke outcome.

Mapping of Crowdsourcing in Health: Systematic Review.

Pharmacogenomic biomarkers as inclusion criteria in clinical trials of oncology-targeted drugs: a mapping of ClinicalTrials.gov.

Post-marketing research and its outcome for novel anticancer agents approved by both the FDA and EMA between 2005 and 2010: A cross-sectional study.

Postmarketing studies for novel drugs approved by both the FDA and EMA between 2005 and 2010: a cross-sectional study

Rituximab for induction and maintenance therapy of granulomatosis with polyangiitis: a single-centre cohort study on 114 patients

Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France, 2004-2012

Should we consider day-2 and day-3 embryo morphology before day-5 transfer when blastocysts reach a similar good quality?

Use of Late-Life Expectancy for Assessing the Long-Term Benefit of Immune Checkpoint Inhibitors

Using an Alzheimer Disease Polygenic Risk Score to Predict Memory Decline in Black and White Americans Over 14 Years of Follow-up